Should governments prioritize funding rare disease research equally with common diseases?

Rare diseases affect millions globally but receive disproportionately less research funding than common illnesses. Regulatory frameworks are evolving to incentivize rare disease drug development, raising questions about fair resource allocation in healthcare systems worldwide.